Quotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer

JERSEY, Channel Islands, Feb. 09, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Christopher Lindop as Chief Financial Officer.  Mr. Lindop will commence his new role on February 15, 2017.

Mr. Lindop joins Quotient with more than a decade of financial leadership experience within high-growth diagnostic and blood management companies. Most recently, Mr. Lindop served as Chief Financial Officer and Executive Vice President of Business Development at Haemonetics Corporation (NYSE:HAE), a publicly traded hematology management company, where he oversaw financial organization, strategic planning, business development and investor relations during a period of rapid growth. Prior to joining Haemonetics in January 2007, Mr. Lindop served as Chief Financial Officer at Inverness Medical Innovations, now Alere Inc., a publicly traded diagnostics company, where he developed a financial infrastructure to support rapid expansion and led multiple financings. Prior to joining Inverness, Mr. Lindop was a Partner at both Arthur Andersen and Ernst & Young. Mr. Lindop currently serves on the Board of Directors at Parexel International (NASDAQ:PRXL), a publicly traded biopharmaceutical consulting company. Mr. Lindop holds a B.A. in Business from the University of Strathclyde (Scotland).

“We are excited to have Chris join us during such a pivotal period as we work towards the commercial launch of MosaiQ^TM,” said Paul Cowan, Quotient’s Chairman and Chief Executive Officer. “His vast experience in helping to lead diagnostic and blood management companies through periods of high growth will be invaluable.”

About Quotient Limited

Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to address the $3.4 billion global transfusion diagnostics market. The Company's operations are based in Switzerland, Scotland and the US.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: Paul Cowan, Chairman & Chief Executive Officer — [email protected]; +1 267 756 0842